Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Conagra adds an ‘On Track’ badge on packaging for 26 of its Healthy Choice frozen meals that call out GLP-1 ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...

Doctors have begun noticing a trend: they all seem to get full before finishing dinner, and it's likely thanks to drugs like ...

Assets in the region include Eli Lilly, Greiner Bio-One, Aptyx, the North Carolina Research Campus, Nufabrx, and SNP Therapeutics. Company information can be accessed using NCBiotech’s company ...

Eli Lilly has followed Novo Nordisk in announcing ... with investment projects ongoing in North Carolina and Indiana in the US. The new facility in Germany is preparing for the future, however ...